BACKGROUND: More than 80,000 postmenopausal breast cancer patients in the United States each year are estimated to begin a 5-year course of aromatase inhibitors (AIs) to prevent recurrence. AI-related arthralgia (joint pain and/or stiffness) may contribute to nonadherence, but longitudinal data are needed on arthralgia risk factors, trajectories, and background in postmenopause. This study sought to describe 1-year arthralgia trajectories and baseline covariates among patients with AI and a postmenopausal comparison group. METHODS: Patients initiating AIs (n = 91) were surveyed at the time of AI initiation and at 6 repeated assessments over 1 year. A comparison group of postmenopausal women without breast cancer (n = 177) completed concomitantly timed surveys. Numeric rating scales (0-10) were used to measure pain in 8 joint pair groups (bilateral fingers, wrists, elbows, shoulders, hips, knees, ankles, and toes). Poisson regression models were used to analyze arthralgia trajectories and risk factors. RESULTS: By week 6, the AI-initiating group had more severe arthralgia than did the comparison group (ratio of means = 1.8, 95% confidence interval = 1.24-2.7, P = .002), adjusting for baseline characteristics. Arthralgia then worsened further over 1 year in the AI group. Menopausal symptom severity and existing joint-related comorbidity at baseline among women initiating AI were associated with more severe arthralgia over time. CONCLUSIONS: Patients initiating AI should be told about the timing of arthralgia over the first year of therapy, and advised that it does not appear to resolve over the course of a year. Menopausal symptoms and joint-related comorbidity at AI initiation can help identify patients at risk for developing AI-related arthralgia.
BACKGROUND: More than 80,000 postmenopausal breast cancerpatients in the United States each year are estimated to begin a 5-year course of aromatase inhibitors (AIs) to prevent recurrence. AI-related arthralgia (joint pain and/or stiffness) may contribute to nonadherence, but longitudinal data are needed on arthralgia risk factors, trajectories, and background in postmenopause. This study sought to describe 1-year arthralgia trajectories and baseline covariates among patients with AI and a postmenopausal comparison group. METHODS:Patients initiating AIs (n = 91) were surveyed at the time of AI initiation and at 6 repeated assessments over 1 year. A comparison group of postmenopausal women without breast cancer (n = 177) completed concomitantly timed surveys. Numeric rating scales (0-10) were used to measure pain in 8 joint pair groups (bilateral fingers, wrists, elbows, shoulders, hips, knees, ankles, and toes). Poisson regression models were used to analyze arthralgia trajectories and risk factors. RESULTS: By week 6, the AI-initiating group had more severe arthralgia than did the comparison group (ratio of means = 1.8, 95% confidence interval = 1.24-2.7, P = .002), adjusting for baseline characteristics. Arthralgia then worsened further over 1 year in the AI group. Menopausal symptom severity and existing joint-related comorbidity at baseline among women initiating AI were associated with more severe arthralgia over time. CONCLUSIONS:Patients initiating AI should be told about the timing of arthralgia over the first year of therapy, and advised that it does not appear to resolve over the course of a year. Menopausal symptoms and joint-related comorbidity at AI initiation can help identify patients at risk for developing AI-related arthralgia.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Ivana Sestak; Jack Cuzick; Francisco Sapunar; Richard Eastell; John F Forbes; Angelo R Bianco; Aman U Buzdar Journal: Lancet Oncol Date: 2008-08-12 Impact factor: 41.316
Authors: Kirsten A Nyrop; Leigh F Callahan; Christine Rini; Mary Altpeter; Betsy Hackney; Amy DePue; Anne Wilson; Arielle Schechter; Hyman B Muss Journal: Support Care Cancer Date: 2016-01-12 Impact factor: 3.603
Authors: Leslie R Schover; George P Baum; Lisa A Fuson; Abenaa Brewster; Amal Melhem-Bertrandt Journal: J Sex Med Date: 2014-08-21 Impact factor: 3.802
Authors: Jennifer Y Sheng; Amanda L Blackford; Aditya Bardia; Raghunandan Venkat; Gedge Rosson; Jon Giles; Daniel F Hayes; Stacie C Jeter; Zhe Zhang; Jill Hayden; Anne Nguyen; Anna Maria Storniolo; Karineh Tarpinian; Norah Lynn Henry; Vered Stearns Journal: Breast Cancer Res Treat Date: 2019-05-11 Impact factor: 4.872
Authors: Kate E Roberts; India T Adsett; Kirsty Rickett; Sophie M Conroy; Mark D Chatfield; Natasha E Woodward Journal: Cochrane Database Syst Rev Date: 2022-01-10
Authors: Liana D Castel; Kenneth A Wallston; Benjamin R Saville; JoAnn R Alvarez; Bradley D Shields; Irene D Feurer; David Cella Journal: Patient Relat Outcome Meas Date: 2015-07-28
Authors: Daniela Polessa Paula; Vanessa I do Brasil Costa; Rosane V Jorge; Flávio F Nobre Journal: Support Care Cancer Date: 2019-05-06 Impact factor: 3.603
Authors: Ioana R Marian; Megan Goff; Jennifer A E Williams; Malvika Gulati; Mae Chester-Jones; Anne Francis; Marion Watson; Tonia L Vincent; Sue Woollacott; Charles Mackworth-Young; Victoria Glover; Dominic Furniss; Matthew Gardiner; Sarah E Lamb; Katy Vincent; Vicki S Barber; Joanna Black; Susan J Dutton; Fiona E Watt Journal: Pilot Feasibility Stud Date: 2021-06-24